Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of … – Nasdaq
|
Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of …
Nasdaq "Shire is leveraging decades of scientific leadership in hemophilia to advance research in gene therapy for this community," said Paul Monahan, M.D., Senior Medical Director, Gene Therapy, Shire. "Drawing from our rich heritage, Shire is well equipped … |
